The effects of aging on tumor growth and angiogenesis are tumor-cell dependent

International Journal of Cancer

Volumn 120, Issue 4, 2007, Pages 753-760

  Reed, May J ^a   Karres, Nathan ^a   Eyman, Daniel ^a   Cruz, Abigail ^a   Brekken, Rolf A ^b   Plymate, Stephen ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Aged; Blood vessels; Matrix metalloproteinases; Mice; Prostate cancer

Indexed keywords

GELATINASE A; GELATINASE B; TESTOSTERONE; VASCULOTROPIN;

AGING; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER TRANSPLANTATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TESTOSTERONE BLOOD LEVEL; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL; ZYMOGRAPHY;

AGING; ANDROGEN-BINDING PROTEIN; ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; BLOOD VESSELS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TESTOSTERONE; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846646456     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22351     Document Type: Article

References (55)

1. Calabrese CT, Adam YG, Volk H. Geriatric colon cancer. Am J Surg 1973;125:181-4.
2. Ershler WB, Socinski MA, Greene CJ. Bronchogenic cancer, metastases and aging. J Am Geriatr Soc 1983;31:673-6.
3. Ershler WB. Why tumors grow more slowly in old people. J Natl Cancer Inst 1986;77:837-9.
4. Ershler WB, Stewart JA, Hacker MP, Moore AL, Tindle BH. B16 murine melanoma and aging: slower growth and longer survival in old mice. J Natl Cancer Inst 1984;72:161-4.
5. Tsuda T, Kim YT, Siskind GW, DeBlasio A, Schwab R, Ershler W, Weksler ME. Role of the thymus and T-cells in slow growth of B16 melanoma in old mice. Cancer Res 1987;47:3097-100.
6. Kreisle R, Stebler B, Ershler W. Effect of host age on tumor-associated angiogenesis in mice. J Natl Cancer Inst 1990;82:44-7.
7. Pili R, Guo Y, Chang J, Nakanishi H, Martin GR, Passaniti A. Altered angiogenesis underlying age-dependent changes in tumor growth. J Natl Cancer Inst 1994;86:1303-14.
8. Ershler WB, Moore AL, Shore H, Gamelli RL. Transfer of age-associated restrained tumor growth in mice by old-to-young bone marrow transplantation. Cancer Res 1984;44:5677-80.
9. Kaptzan T, Skutelsky E, Itzhaki O, Sinai J, Huszar M, Siegal A, Ben-Zvi R, Jossiphov J, Michowitz M, Schiby G, Leibovici J. Efficacy of anti-angiogenic treatment of tumors in old versus young mice. Mech Ageing Dev 2006;127:398-409.
10. Ershler WB. Explanations for reduced tumor proliferative capacity with age. Exp Gerontol 1992;27:551-8.
11. Donin N, Sinai J, Michowitz M, Hiss J, Nordenberg J, Leibovici J. Role of immune response as determinant of tumor progression in function of host age in the B16 melanoma. Mech Ageing Dev 1995;80:121-37.
12. Holbrook NJ, Ikeyama S. Age-related decline in cellular response to oxidative stress: links to growth factor signaling pathways with common defects. Biochem Pharmacol 2002;64:999-1005.
13. Itzhaki O, Kaptzan T, Skutelsky E, Sinai J, Michowitz M, Siegal A, Schibi G, Huszar M, Ben-Dor L, Leibovici J. Age-adjusted antitumoral therapy based on the demonstration of increased apoptosis as a mechanism underlying the reduced malignancy of tumors in the aged. Biochim Biophys Acta 2004;1688:145-59.
14. Kaptzan T, Skutelsky E, Itzhaki O, Sinai J, Michowitz M, Yossipov Y, Schiby G, Leibovici J. Age-dependent differences in the efficacy of cancer immunotherapy in C57BL and AKR mouse strains. Exp Gerontol 2004;39:1035-48.
15. DePinho RA. The age of cancer. Nature 2000;408:248-54.
16. Balducci L, Ershler WB. Cancer and ageing: a nexus at several levels. Nat Rev Cancer 2005;5:655-62.
17. Reed MJ, Edelberg JM. Impaired angiogenesis in the aged. Sci Aging Knowledge Environ 2004;2004:pe7.
18. Campisi J. Senescent cells, tumor suppression and organismal aging: good citizens, bad neighbors. Cell 2005;120:513-22.
19. Anisimov VN. Effect of host age on tumor growth rate in rodents. Front Biosci 2006;11:412-22.
20. Marinho A, Soares R, Ferro J, Lacerda M, Schmitt FC. Angiogenesis in breast cancer is related to age but not to other prognostic parameters. Pathol Res Pract 1997;193:267-73.
21. Fisher CJ, Egan MK, Smith P, Wicks K, Millis RR, Fentiman IS. Histopathology of breast cancer in relation to age. Br J Cancer 1997;75:593-6.
22. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000;82:812-7.
23. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9 (Suppl 1):2-10.
24. Nicholson B, Gulding K, Conaway M, Wedge SR, Theodorescu D. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach. Clin Cancer Res 2004;10:8728-34.
25. Gronberg H, Damber JE, Jonsson H, Lenner P. Patient age as a prognostic factor in prostate cancer. J Urol 1994;152:892-5.
26. Foster B, Gingrich J, Kwon E, Madias C, Greenberg N. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997;57:3325-30.
27. Freeman KW, Gangula RD, Welm BE, Ozen M, Foster BA, Rosen JM, Ittmann M, Greenberg NM, Spencer DM. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. Cancer Res 2003;63:6237-43.
28. Nikitina EY, Desai SA, Zhao X, Song W, Luo AZ, Gangula RD, Slawin KM, Spencer DM. Versatile prostate cancer treatment with inducible caspase and interleukin-12. Cancer Res 2005;65:4309-19.
29. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peacocke M, Campisi J. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995;92:9363-7.
30. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL, Plymate SR. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005;11:3065-74.
31. Feng D, Nagy JA, Brekken RA, Pettersson A, Manseau EJ, Pyne K, Mulligan R, Thorpe PE, Dvorak HF, Dvorak AM. Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors. J Histochem Cytochem 2000;48:545-56.
32. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
33. Pfaffl MW, Morgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002;30: e36.
34. Reed M, Corsa A, Penn P, Pendergrass W, Sage E, Abrass I. Neovascularization of sponge implants in aged mice: delayed angiogenesis is coincident with decreased levels of TGF-β1 and type I collagen. Am J Pathol 1998;152:113-23.
35. Puolakkainen PA, Reed MJ, Gombotz WR, Twardzik DR, Abrass IT, Sage EH. Acceleration of wound healing in aged rats by topical application of transforming growth factor-β1. Wound Repair Regen 1995;3:330-39.
36. Hallmann R, Mayer DN, Berg EL, Broermann R, Butcher EC. Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier. Dev Dyn 1995;202:325-32.
37. Sadoun E, Reed MJ. Impaired angiogenesis in aging is associated with alterations in vessel density, matrix composition, inflammatory response, and growth factor expression. J Histochem Cytochem 2003;51:1119-30.
38. Zcharia E, Zilka R, Yaar A, Yacoby-Zeevi O, Zetser A, Metzger S, Sarid R, Naggi A, Casu B, Ilan N, Vlodavsky I, Abramovitch R. Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J 2005;19:211-21.
39. Ntais C, Polycarpou A, Tsatsoulis A. Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol 2003;149:469-77.
40. Stefanou D, Batistatou A, Kamina S, Arkoumani E, Papachristou DJ, Agnantis N. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer. In Vivo 2004;18:155-60.
41. Koos RD, Kazi AA, Roberson MS, Jones JM. New insight into the transcriptional regulation of vascular endothelial growth factor expression in the endometrium by estrogen and relaxin. Ann N Y Acad Sci 2005;1041:233-47.
42. St-Pierre Y, Couillard J, Van Themsche C. Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and inflammatory diseases. Expert Opin Ther Targets 2004;8:473-89.
43. Tester AM, Waltham M, Oh SJ, Bae SN, Bills MM, Walker EC, Kem FG, Stetler-Stevenson WG, Lippman ME. Thompson EW. Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice. Cancer Res 2004;64:652-8.
44. Mancini A, Di Battista JA. Transcriptional regulation of matrix metalloprotease gene expression in health and disease. Front Biosci 2006;11:423-46.
45. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005;87:287-97.
46. Swift ME, Kleinman HK, DiPietro LA. Impaired wound repair and delayed angiogenesis in aged mice. Lab Invest 1999;79:1479-87.
47. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29 (6 Suppl 16):15-8.
48. Fidler IJ, Ellis LM. Neoplastic angiogenesis-not all blood vessels are created equal. N Engl J Med 2004;351:215-6.
49. Francis MK, Appel S, Meyer C, Balin SJ, Balin AK, Cristofalo VJ. Loss of EPC-1/PEDF expression during skin aging in vivo. J Invest Dermatol 2004;122:1096-105.
50. Ogata N, Matsuoka M, Imaizumi M, Arichi M, Matsumura M. Decrease of pigment epithelium-derived factor in aqueous humor with increasing age. Am J Ophthalmol 2004;137:935-6.
51. Phillips JA, Bonassar LJ. Matrix metalloproteinase activity synergizes with α2β1 integrins to enhance collagen remodeling. Exp Cell Res 2005;310:79-87.
52. Stuelten CH, DaCosta Byfield S, Arany PR, Karpova TS, Stetler-Stevenson WG, Roberts AB. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-α and TGF-β. J Cell Sci 2005;118 (Pt 10):2143-53.
53. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M, Stearns ME. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997;15:246-58.
54. Stearns ME, Stearns M. Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a)expression in human prostate cancer. Oncol Res 1996;8:63-7.
55. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.